Nelson Van Denburg & Campbell Wealth Management Group LLC Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Nelson Van Denburg & Campbell Wealth Management Group LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 1.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 20,885 shares of the company’s stock after selling 396 shares during the quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $2,701,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in JNJ. Billeaud Capital Management Inc. increased its stake in shares of Johnson & Johnson by 0.4% during the second quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock valued at $6,130,000 after buying an additional 169 shares during the period. Meeder Asset Management Inc. raised its position in Johnson & Johnson by 11.1% during the 2nd quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock valued at $15,277,000 after purchasing an additional 10,927 shares in the last quarter. Archford Capital Strategies LLC raised its position in Johnson & Johnson by 11.2% during the 2nd quarter. Archford Capital Strategies LLC now owns 21,997 shares of the company’s stock valued at $3,064,000 after purchasing an additional 2,211 shares in the last quarter. Marino Stram & Associates LLC raised its position in Johnson & Johnson by 1.2% during the 2nd quarter. Marino Stram & Associates LLC now owns 32,199 shares of the company’s stock valued at $4,485,000 after purchasing an additional 380 shares in the last quarter. Finally, Palisades Hudson Asset Management L.P. raised its position in Johnson & Johnson by 42.6% during the 2nd quarter. Palisades Hudson Asset Management L.P. now owns 2,241 shares of the company’s stock valued at $312,000 after purchasing an additional 669 shares in the last quarter. 72.01% of the stock is owned by institutional investors.

JNJ has been the subject of a number of research analyst reports. Raymond James decreased their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research report on Wednesday, July 17th. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Bank of America reaffirmed a “hold” rating and issued a $150.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 16th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Finally, Barclays started coverage on Johnson & Johnson in a report on Friday, June 21st. They issued a “hold” rating and a $140.00 price target for the company. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $150.60.

Shares of JNJ traded down $1.80 during mid-day trading on Wednesday, hitting $130.04. 1,636,133 shares of the company’s stock were exchanged, compared to its average volume of 7,077,218. The firm has a fifty day moving average of $130.02 and a two-hundred day moving average of $135.08. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The stock has a market cap of $352.75 billion, a price-to-earnings ratio of 15.90, a P/E/G ratio of 2.26 and a beta of 0.69. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the prior year, the business posted $2.10 EPS. Johnson & Johnson’s quarterly revenue was down 1.3% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $0.95 per share. The ex-dividend date was Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.92%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is a dead cat bounce?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.